Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04207619 · ClinicalTrials.gov registry record · NA

Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation

A NA study of Diabetes and Hypoglycemia, sponsored by Pennington Biomedical Research Center.

Recruiting
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT04207619: Recruiting NA study of Diabetes and Hypoglycemia, sponsored by Pennington Biomedical Research Center.

NCT04207619 is a NA study of Diabetes and Hypoglycemia that is actively recruiting participants, run by Pennington Biomedical Research Center. The registered enrollment target is 10 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04207619, a NA study of Diabetes and Hypoglycemia, is actively recruiting participants, sponsored by Pennington Biomedical Research Center.

RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

Hypoglycemic complications are a major impediment to the maintenance of healthy glucose levels in persons with diabetes. The investigators recently completed a clinical pilot and feasibility study (GLIMPSE, NCT02690168), which identified a novel biomarker, glial acetate metabolism, that appears to predict the susceptibility to hypoglycemia. By providing an assay to predict hypoglycemic events and therefore diabetic complications, the development of this biomarker could significantly improve the treatment of persons with diabetes. The goal of this study is to determine the efficacy of our biomarker for predicting susceptibility to insulin-induced hypoglycemia. In order to accomplish this goal the investigatiors will pair our 13C magnetic resonance spectroscopy procedure to assess glial acetate metabolism, developed in the GLIMPSE study, with a hyperinsulinemic-hypoglycemic clamp procedure, developed in the HYPOCLAMP study (NCT03839511). The two procedures will be separated by a three day interval. The investigators will then correlate the participants' rates of glial acetate metabolism with their neuroendocrine responses to the hypoglycemic clamp. This proof of concept study will test the hypothesis that glial acetate metabolism is inversely proportional to the neuroendocrine response to hypoglycemia, that is, as glial acetate metabolism increases the neuroendocrine response will decrease.

Primary Outcome

Glial acetate metabolism

Conditions Studied

Interventions

  • OTHER hyperinsulinemic-hypoglycemic clamp
  • OTHER 13C-MRS procedure/Acetate infusion

Study Locations (1)

Louisiana

  • Pennington Biomedical Research Center - Baton Rouge

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2020-02-19
Est. Completion 2026-09
Phase NA

What NCT04207619 shows while recruiting

NCT04207619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which hyperinsulinemic-hypoglycemic clamp is the first listed.

NCT04207619 reports a single indexed study location in Louisiana.

Frequently Asked Questions

What is clinical trial NCT04207619 about?

NCT04207619 is a clinical study titled "Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation". Hypoglycemic complications are a major impediment to the maintenance of healthy glucose levels in persons with diabetes. The investigators recently completed a clinical pilot and feasibility study (GLIMPSE, NCT02690168), which identified a novel biomarker, glial acetate metabolism, that appears to p...

What is the current status of trial NCT04207619?

This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2020-02-19. Estimated completion is 2026-09.

What conditions does trial NCT04207619 study?

This clinical trial studies the following conditions: Diabetes, Hypoglycemia.

What interventions are being tested in trial NCT04207619?

The interventions under investigation include: hyperinsulinemic-hypoglycemic clamp (OTHER), 13C-MRS procedure/Acetate infusion (OTHER).

Who is sponsoring clinical trial NCT04207619?

This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04207619 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04207619's enrollment target sits among peer trials

10 330th of 338 higher than 5 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04207619, the US trial registry maintained by the National Library of Medicine. NCT04207619 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.